Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial - The Lancet Respiratory Medicine
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) | SpringerLink
Frontiers | Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways | Pharmacology
Epidemiology of lung cancer - ppt download
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers - Lung Cancer
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) - ESMO Open
PPT - Lung Cancer Patients with PS=3: PowerPoint Presentation, free download - ID:5776246
P2.17-02 Survival in Performance Status 3 Non-Small Cell Lung Cancer Patients Receiving Radical Radiotherapy - Journal of Thoracic Oncology
Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival - ScienceDirect
Effects of different metastasis patterns, surgery and other factors on the prognosis of patients with stage IV non‑small cell lung cancer: A Surveillance, Epidemiology, and End Results (SEER) linked database analysis
The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment - Sueoka‐Aragane - - Cancer Medicine - Wiley Online Library
Early mortality in lung cancer: French prospective multicentre observational study – topic of research paper in Health sciences. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales - Lung Cancer
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors - Clinical Lung Cancer
Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status - Adachi - 2020 - Cancer Medicine - Wiley Online Library
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301) - Journal
Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice | Anticancer Research
The current treatment landscape in the UK for stage III NSCLC | British Journal of Cancer
Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry
Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research - ScienceDirect
Stage 3 Lung Cancer: Survival Rate, Prognosis, and More
Dose surface maps of the heart can identify regions associated with worse survival for lung cancer patients treated with radiotherapy - Physics and Imaging in Radiation Oncology
Immunotherapy Improves Five-year Survival Rate of People with Advanced Lung Cancer - U Magazine - UCLA Health - Los Angeles, CA
Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival - ScienceDirect
α Syn Phospho (Abcam) | Bioz | Ratings For Life-Science Research
